Profile data is unavailable for this security.
About the company
Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading of pharmaceutical products like medicines, injections and other related products. The Company’s product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, liquid injection, and pharma products. It offers products for anti-infective, respiratory system, gynecology, cardio and CNS (central nervous system), antibacterial, anti-diabetic, and anti-malaria. The Company serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia, and 26 states across India. The Company's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms), and Tinnex Capsule used to treat tinnitus.
- Revenue in INR (TTM)5.92bn
- Net income in INR979.63m
- Incorporated1995
- Employees1.70k
- LocationLincoln Pharmaceuticals LtdLINCOLN HOUSE, B/h. Satyam ComplexScience City Road, SolaAHMEDABAD 380060IndiaIND
- Phone+91 7 967778000
- Fax+91 7 930018062
- Websitehttps://www.lincolnpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bajaj Healthcare Ltd | 4.76bn | -133.27m | 11.38bn | 944.00 | -- | -- | 77.32 | 2.39 | -4.82 | -10.30 | 172.62 | -- | -- | -- | -- | 5,041,608.00 | -- | 7.67 | -- | 14.11 | 48.43 | 33.26 | -2.80 | 7.99 | -- | 1.74 | -- | 4.90 | -26.69 | 5.04 | -122.55 | -- | 15.08 | -- |
| Ngl Fine Chem Ltd | 3.58bn | 420.29m | 12.21bn | 390.00 | 29.06 | -- | 31.67 | 3.41 | 68.03 | 68.03 | 580.00 | -- | -- | -- | -- | 9,188,328.00 | -- | 15.06 | -- | 19.58 | 52.02 | 43.53 | 11.73 | 13.15 | -- | 26.59 | -- | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Bliss GVS Pharma Ltd | 8.00bn | 634.20m | 13.01bn | 831.00 | 20.79 | 1.29 | 13.06 | 1.63 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| JG Chemicals Ltd | -100.00bn | -100.00bn | 13.44bn | 56.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Lincoln Pharmaceuticals Ltd | 5.92bn | 979.63m | 13.62bn | 1.70k | 13.90 | -- | 12.46 | 2.30 | 48.91 | 48.91 | 295.69 | -- | -- | -- | -- | 3,483,600.00 | -- | 13.95 | -- | 16.54 | 51.92 | 50.65 | 16.54 | 14.71 | -- | 60.93 | -- | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Kopran Ltd | 6.37bn | 592.79m | 13.84bn | 358.00 | 19.77 | -- | 19.01 | 2.17 | 14.53 | 14.53 | 150.01 | -- | -- | -- | -- | 17,794,040.00 | -- | 8.47 | -- | 12.23 | 36.03 | 32.93 | 9.31 | 8.89 | -- | 27.17 | -- | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.27bn | 243.00m | 14.37bn | 1.03k | 60.46 | 7.29 | 50.38 | 6.34 | 8.98 | 8.98 | 83.78 | 74.42 | 0.9703 | 5.13 | 9.92 | 2,213,181.00 | 10.39 | 10.95 | 12.40 | 13.29 | 58.16 | 58.13 | 10.71 | 9.21 | 2.60 | 32.84 | 0.0474 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 15.42bn | 48.00 | 70.08 | 17.75 | 57.37 | 7.26 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Zota Health Care Ltd | 1.98bn | -242.34m | 16.03bn | 445.00 | -- | -- | 3,431.57 | 8.09 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Sigachi Industries Ltd | 4.10bn | 594.65m | 16.44bn | 991.00 | 30.75 | -- | 23.11 | 4.01 | 1.60 | 1.60 | 10.97 | -- | -- | -- | -- | 4,136,886.00 | -- | 14.77 | -- | 19.57 | 52.33 | 50.30 | 14.43 | 14.92 | -- | 7.19 | -- | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| Beta Drugs Ltd | 2.96bn | 364.37m | 18.43bn | 371.00 | 50.57 | 11.73 | 39.86 | 6.23 | 37.90 | 37.90 | 307.59 | 163.43 | 1.31 | 4.51 | 4.17 | 7,970,723.00 | 16.10 | 15.10 | 23.91 | 22.23 | 38.73 | 39.77 | 12.32 | 12.38 | 1.51 | 17.81 | 0.0654 | 0.00 | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Acadian Asset Management LLCas of 30 Sep 2024 | 21.35k | 0.11% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 19.55k | 0.10% |
| American Century Investment Management, Inc.as of 03 Oct 2024 | 17.24k | 0.09% |
| State Board of Administration of Florida Retirement Systemas of 30 Jun 2024 | 6.30k | 0.03% |
| Fidelity Management & Research Co. LLCas of 31 Aug 2024 | 5.46k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 1.44k | 0.01% |
| DFA Australia Ltd.as of 31 Aug 2024 | 70.00 | 0.00% |
| Carne Global Fund Managers (Ireland) Ltd.as of 30 Sep 2023 | 0.00 | 0.00% |
